Heron Therapeutics HRTX
NASDAQ HRTX
$0.35 -0.01 (-2.78%)
At close: Oct 2, 2026 · 4:00 PM EDT

Heron Therapeutics (HRTX) Gains from Sales and Divestitures (2017 - 2025)

Updated

Heron Therapeutics (HRTX) reported Gains from Sales and Divestitures of -$129,000 for Q2 2025.

Analysis

Heron Therapeutics (HRTX) Gains from Sales and Divestitures (2017 - 2025) Analysis & Trends

For FY2024, Heron Therapeutics posted Gains from Sales and Divestitures of $27,000.

  • By year, Gains from Sales and Divestitures came in at -$10,000 in FY2023, -$74,000 in FY2022 and -$822,000 in FY2021.
  • The Q2 2025 figure ranks as the lowest quarterly Gains from Sales and Divestitures in data going back to Q1 2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Heron Therapeutics 66.45 Mn -123.12 Mn 26.09 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -129,000.00
Mar 31, 2025 34,000.00
Dec 31, 2023 13,000.00
Sep 30, 2022 22,000.00
Mar 31, 2022 -96,000.00
Dec 31, 2019 -9,000.00
Jun 30, 2019 -1,000.00
Mar 31, 2019 -52,000.00
Dec 31, 2018 -26,000.00
Dec 31, 2017 -46,000.00
Sep 30, 2017 12,000.00
Mar 31, 2017 -5,000.00
API Access

Heron Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=HRTX&period=max&api_key=YOUR_API_KEY